HomeTrading IdeasRisk Assets Rebound as...

Risk Assets Rebound as Trump Pushes Tariff Deadline to August 1

After a volatile past day session, this one was way calmer as Trump announced yet another delay in tariff deadlines – From the approaching July 9th to August 1st, apparently the final warning.

The session began with the leading to the upside, followed by general mean-reversion all across asset classes. It seems that participants will be awaiting more headlines/economic data before moving further.

The biggest winner of the day was , which got propped up by the latest announcement of 50% tariffs on all US Imports – CME Futures finish the session up close to 10%, marking session highs at $5.89.

Other metals and cryptocurrencies finish the day mostly higher but by a small margin, benefiting from the afternoon USD selling – Only finished down close to 1%.

Daily Cross-Asset Performance

Source: TradingView

continues outperforming other assets, and Gold is at the other end of the performance spectrum.

Other assets are all contained within a +/- 1% range, with the USD giving back its overnight/morning upside after the latest tariff pushback.

A Picture of Performance for Major CurrenciesPerformance of Major Currencies

Source: OANDA Labs

The trend continues with yet again being the weakest of majors, and the profiting from the unexpected Rate Hold.

The day had started with the Greenback leading against every other of its major counterparts, but gave back its lead on a short-term breakout rejection. The Dollar still broke above its May Weekly descending Channel, a story that needs to be monitored closely.

Economic Calendar

A look at the Economic Data release

Except for tonight’s 9:30 Chinese (not very market-moving) and 10:00 P.M. RBA Rate Decision, the calendar for today’s session will not see much in terms of economic data releases.

Still, brace up for ECB Speakers all around today session, and the releasing at 2:00 P.M. today which, in the absence of much recent communication from the , may this time move markets – despite being marked as a high-tier release, it tends to be a snoozer most times as usually, nothing new is being said compared to previous communications.

Safe Trades!

Original Post

Most Popular

More from Author

What To Expect From Johnson & Johnson’s Q2 Earnings – Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson JNJ is set to release its second-quarter earnings...

Why Is Kazia Stock Soaring Today – Kazia Therapeutics (NASDAQ:KZIA)

Kazia Therapeutics KZIA on Wednesday reported preliminary results from the first...

What To Expect From Eli Lilly’s Q2 Earnings – Eli Lilly (NYSE:LLY)

Eli Lilly and Co. LLY is set to release its second-quarter...

Amazon, Defense Stocks in Spotlight Amid Trade and Consumer Uncertainty

US stocks are modestly higher as investors weigh up the latest...

Read Now

What To Expect From Johnson & Johnson’s Q2 Earnings – Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson JNJ is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85 billion.While overall estimates for 2025 and beyond show only slight increases, investor attention is expected...

Why Is Kazia Stock Soaring Today – Kazia Therapeutics (NASDAQ:KZIA)

Kazia Therapeutics KZIA on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s MRK Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of dosing.The patient, a 61-year-old woman with metastatic...

What To Expect From Eli Lilly’s Q2 Earnings – Eli Lilly (NYSE:LLY)

Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity...

Amazon, Defense Stocks in Spotlight Amid Trade and Consumer Uncertainty

US stocks are modestly higher as investors weigh up the latest announcements from President Trump and watch for further trade developments. President Trump announced plans to impose 50% tariffs on imports, sending prices sharply higher. US copper prices shot 13% higher, closing at a record high of...

Rhythm Pharma’s Oral Drug For Rare Obesity Shows Promise – Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc. RYTM on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.Hypothalamic obesity is a rare type of obesity resulting from damage to the hypothalamus, a brain region...

Gilead’s Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million – Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).Through the agreement, Gilead will supply enough...

Markets Today: RBNZ Rate Hold, Copper Volatility, DAX Moves Toward Fresh Highs

Chinese stocks are set to hit their highest level in three years as investors hope for new steps to fight deflation and boost the economy. Meanwhile, dropped in London after President Donald Trump issued a new tariff warning.Asian Market WrapThe Shanghai Stock Exchange Composite Index rose...

FDA Approves New Dosing Schedule For Eli Lilly’s Kisunla In Alzheimer’s Treatment – Eli Lilly (NYSE:LLY)

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s LLY Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA approved the drug in July 2024.In the TRAILBLAZER-ALZ 6...

H2 2025: Room for Optimism, Risk for Complacency

Reasons To Be Fearful, Reasons To Be Cheerful It was an eventful first half of the year, to say the least... In January, the rise of DeepSeek was a wake-up call for the world, demonstrating that China is a major competitor to the US in AI and technology. The...

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug – Merck & Co (NYSE:MRK), Verona Pharma (NASDAQ:VRNA)

Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.Through the acquisition of this respiratory disease-focused company, Merck...

The Energy Report: Demand Exceeding Supply

It’s the oldest story in the book. Prices go up when demand exceeds supply, not only in oil and products but in wholesale power, driving up electricity costs. The Energy Information Administration (EIA) in its Short-Term Energy Outlook confirmed that we have a global supply deficit. Not only...

Altcoin Rotation Gains Steam as Bitcoin and Ethereum Take a Backseat

Despite increasing trade tensions and tariff worries, crypto continues to hold up. More than that, the group is actually performing pretty well. is leaning on a potential breakout, but it’s not doing the heavy lifting right now. To some extent, neither is . Instead, it’s more broad. Stellar,...